On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck MRK reported fourth-quarter 2024 adjusted ... million compared with $149 million in the previous quarter. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter.

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development.

For the quarter ended December 2024, Merck (MRK) reported revenue of $15.62 billion, up 6.8% over the same period last year. EPS came in at $1.72, compared to $0.03 in the year-ago quarter. The ...

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...

Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania ...